IL6 and COVID-19: Although preliminary experiences suggest that IL-6 blockade is relatively safe in post-transplant COVID-19, the risk of potentially severe adverse events and the absence of conclusive evidence on the clinical benefit to be expected from TCZ therapy should be carefully balanced in the clinical decision-making process.